Mandy Jackson

Mandy Jackson

Managing Editor, US Commercial News

San Diego, CA

Mandy reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy. Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.

Latest from Mandy Jackson

Finance Watch: CEO Bischofberger Exits As Kronos Cuts 83% Of Workforce

Restructuring Edition: Kronos is laying off most of its employees as it considers strategic options, including a potential sale of its assets. Also, Agenus is restructuring and other companies revealed job cuts in Q3 earnings reports, including Sensei, AN2, NextCure and Aurinia.

Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For

Much anticipated Phase II results in obesity for Amgen’s GLP-1 agonist/GIP antagonist showed up to 20% weight loss, but without detailed data the drug’s competitiveness is hard to ascertain.

Cassava’s Alzheimer’s Drug Fails In First Phase III, Second Pivotal Trial Stopped

After years of controversy, simufilam did not achieve statistical significance on any endpoints in ReThink-ALZ, so the company ended ReFocus-ALZ and its long-term extension study.

Finance Watch: Adcendo Pursues Proof-Of-Concept With $135m Series B Round

Private Company Edition: The Danish ADC developer, after extending its series A twice, raised a series B to take multiple programs into the clinic. Also, Neurelis sold its Neffy royalties for $208m, Enveda closed a $130m series C round and C Ray’s series A+ financing raised $100m-plus.

Financial Market Conditions Still Choppy As Rising Tide Has Yet To Lift All Ships

Venture capital funding is up, and initial and follow-on public offerings are growing, but the building wave of investment in biopharma has not reached all companies.

Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown

With a US FDA determination that sotagliflozin cannot be approved for type 1 diabetes at this time, Lexicon is shutting down its commercial organization to focus on its R&D pipeline.